The MSI2 antibody targets the Musashi homolog 2 (MSI2) protein, a member of the Musashi family of RNA-binding proteins. MSI2 is primarily recognized for its role in post-transcriptional regulation of gene expression by binding to specific mRNA targets, influencing translation, stability, and localization. It is critical in stem cell maintenance, neurodevelopment, and oncogenesis. In stem cells, MSI2 promotes self-renewal by repressing differentiation-associated mRNAs, such as Numb and p21. Dysregulation of MSI2 is linked to various cancers, including leukemia, glioblastoma, and colorectal cancer, where its overexpression correlates with tumor progression, metastasis, and therapy resistance. MSI2 antibodies are widely used in research to investigate its expression patterns, functional mechanisms, and interactions in both physiological and pathological contexts. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in biomarker studies and therapeutic target validation. Validation of MSI2 antibodies typically involves knockout controls or siRNA knockdown to confirm specificity. As an onconeural protein, MSI2 continues to be a focus in cancer biology and regenerative medicine research.